RESEARCH AGREEMENTResearch Agreement • April 26th, 2005 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Michigan
This RESEARCH AGREEMENT (this “Agreement”) is entered into as of March 5, 2005 (the “Effective Date”) by and between Interleukin Genetics, Inc., a Delaware corporation having its principal office at 135 Beaver Street, Waltham, MA 02452 (“IG”) and Access Business Group LLC, having its principal office at 7575 Fulton Street, East, Ada, Michigan 49355-0001 (“Access”). Each of IG and Access is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
FIRST AMENDMENTDistribution Agreement • April 26th, 2005 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances
THIS FIRST AMENDMENT TO DISTRIBUTION AGREEMENT (the “Amendment”) is made and entered as of March 5, 2005, between ACCESS BUSINESS GROUP INTERNATIONAL LLC, a Michigan limited liability company, with its principal place of business at 7575 East Fulton Road, Ada, Michigan 49355 (“Access”) and INTERLEUKIN GENETICS INC., a Delaware corporation with its principal place of business at 135 Beaver Street, Waltham, Massachusetts 02452 (“Seller”).
RESEARCH AGREEMENTResearch Agreement • April 26th, 2005 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Michigan
This RESEARCH AGREEMENT (this “Agreement”) is entered into as of March 5, 2005 (the “Effective Date”) by and between Interleukin Genetics, Inc., a Delaware corporation having its principal office at 135 Beaver Street, Waltham, MA 02452 (“IG”) and Access Business Group LLC, having its principal office at 7575 Fulton Street, East, Ada, Michigan 49355-0001 (“Access”). Each of IG and Access is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
TO STOCK PURCHASE AGREEMENTStock Purchase Agreement • April 26th, 2005 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances
THIS SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT (the “Amendment”) is made and entered as of March 5, 2005, between PYXIS INNOVATIONS INC., a Delaware corporation (“Investor”), and INTERLEUKIN GENETICS INC., a Delaware corporation (the “Company”).
